Innate Pharma
Tracked across 5 events · 35 articles · First seen Apr 02, 2026 · Last active Aug 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Innate Pharma filed its 2025 Universal Registration Document and Form 20-F annual report, fulfilling regulatory obligations for publicly traded companies.
Apr 02, 2026 · 7 articles
Business
Impact: Innate Pharma will present its oncology pipeline and strategies at the AACR Oncology Industry Partnering Event, providing an opportunity to attract investors and accelerate therapy development.
Apr 08, 2026 · 6 articles
Regulatory
Impact: Innate Pharma released its total number of shares outstanding and voting rights as of April 9, 2026, in compliance with French regulatory requirements.
Apr 13, 2026 · 6 articles
Business
Impact: Innate Pharma announced the voting results of its Annual General Meeting, which is a routine corporate governance event. The event confirms the company's adherence to regulatory requirements and shareholder engagement.
May 22, 2026 · 6 articles
Business
Swedish Orphan Biovitrum (Sobi) and Innate Pharma announced a strategic partnership to develop and commercialize lacutamab, a first-in-class anti-KIR3DL2 antibody for cutaneous T-cell lymphoma (CTCL). Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3…
Impact: Innate receives $75 million upfront and up to $505 million in milestones plus royalties, funding its Phase 3 trial and providing validation for its pipeline.
Aug 10, 2026 · 10 articles
90
Swedish Orphan Biovitrum entered partnership Innate PharmaSobi and Innate Pharma...
85
Innate Pharma will conductSobi and Innate Pharma...
70
Innate Pharma will receiveSobi and Innate Pharma...
ERGEN INTELLIGENCE
Track Innate Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard